1037 results about "Phospholipin" patented technology

The first aspect of the invention relates to a bispecific antibody, which comprises a first functional domain for specific identification of phosphatidylinositol protein polysaccharide-3, a second domain for specific identification of human T cell antigen CD3, and a connection for connecting the functional domains. The second aspect of the invention relates to a nucleotide sequence encoding the above antibody. The third aspect of the invention relates to a carrier containing the above nucleotide sequence, and includes an expressive vector. The fourth aspect of the invention relates to a eukaryotic or prokaryotic expression system containing the above carrier. The fifth aspect of the invention relates to application of the above antibody to preparation of medicament for treating or preventing tumor.

The invention discloses a whitening agent liposome coating micro-capsule composition as well as a preparation method and an application thereof. The whitening agent liposome coating micro-capsule composition comprises 5-30% of whitening agent, 2-50% of polyhydric alcohol, 1-30% of phospholipids, 1-30% of grease, 1-10% of emulsifying agent and 1-30% of deionized water, wherein the whitening agent is coated by lecithin which is very similar to a skin lipid structure and is prone to penetrating into the deep layer of skin, thus the defect that the whitening agent is unlikely to be absorbed by the skin is overcome; the whitening agent coated by lecithin is isolated from oxygen in air, thus the detect that the whitening agent is prone to being oxidized and discoloring is solved; when whitening products containing the whitening agent liposome coating micro-capsule composition are used, the whitening agent is slowly released and has a long-time whitening effect.

The present invention relates to a frozen confection product comprising one or more proteins and a whey protein phospholipid concentrate. Preferably the frozen confection product is prepared by using a standard freezing step followed by low temperature extrusion and by acidifying the ingredient mix for preparing the frozen confection product. The present invention also relates to a method of preparing such product.

The invention is a low viscosity oil-in-water emulsion that is readily atomizable for use in cosmetic and dermatological applications and particularly for spray or aerosol applications. The oil-in-water emulsion includes at least one phospholipid and at least one oil-in water emulsifier. In some embodiments, the emulsion may also include a water-in-oil emulsifier. The invention also includes a process for preparing the emulsion.

A breviscapine-phosphotide composition in the form of oral preparation or injection is prepared from breviscapine and soybean (or egg yolk, or synthetic) lecithine in a wt ratio of 1:(0.5-50) through heating, reflux, washing and drying. Its advantages are high stability and durability, and quickly taking its curative effect.

An environmentally friendly grease composition is provided comprising (a) a vegetable oil and (b) a cellulose fiber. The grease may further comprise glycerin; a rust inhibitor; and/or a fatty acid ester, lecithin, phosphatidyl choline, or a combination thereof.

The invention provides a feed additive, feed and preparation method thereof for preventing nutritional fatty liver of fish. Optimized compound of choline chloride, bile acid, carnitine, betaine and phospholipids is added into pellet feed for feeding fish, which can obviously reduce the settlement of fat in liver of fish caused by nutrient induction, avoid the generation of fatty liver diseases and promote the healthy growth of fish.

The present invention relates to methods, monitors and systems measuring lysophosphatidylcholine, its derivatives and/or procalcitonin as well as at least one clinical marker (e.g. temperature or respiration rate) and/or at least one biomarker for the early detection of sepsis in a subject.

The present invention relates to hovel fused azolepyrimidine derivatives, processes for preparing them and pharmaceutical preparations containing them. The fused azolepyrimidine derivatives of the present invention exhibit enhanced potency for phosphotidylinositol-3-kinase (PI3K) inhibition, especially for PI3K-γ inhibition and can be used for the prophylaxis and treatment of diseases associated with PI3K and particularly with PI3K-γ activity. More specifically, the azole derivatives of the present invention are useful for treatment and prophylaxis of diseases as follows: inflammatory and immunoregulatory disorders, such as asthma, atopic dermatitis, rhinitis, allergic diseases, chronic obstructive pulmonary disease (COPD), septic shock, joint diseases, autoixnmune pathologies such as rheumatoid arthritis, and Graves' disease, cancer, myocardial contractility disorders, heart failure, thromboembolism, ischemia, and atherosclerosis. The compounds of the present invention are also useful for pulmonary hypertension, renal failure, cardiac hypertrophy, as well as neurodegenerative disorders such as Parkinson's disease, Alzheimer's disease, diabetes and focal ischemia, since the diseases also relate to PI3K activity in a human or animal subject.

The invention discloses a method for extracting squalene by using camellia oleosa seeds as raw materials and tea oil and squalene soft capsules and relates to the technical field of biomedicine. The extraction method comprises the following process flows of material preparation, grinding, leaching, concentration, methyl esterification, complexant-borax reaction, macroporous resin chromatographic separation and purification, concentration, extraction, washing, concentration, preparation of squalene crude oil and supercritical carbon dioxide extraction, so that squalene essential oil with the squalene content of more than or equal to 80 percent is obtained. The tea oil and squalene soft capsules are prepared from the following raw materials in percentage by weight: 87 to 90 percent of squalene essential oil with the squalene content of more than or equal to 80 percent, 3 to 5 percent of polyethylene glycol 400, 2 to 3 percent of beewax and 2 to 5 percent of phospholipid. The raw material resources are wide. The prepared tea oil and squalene soft capsules not only can be used for medicine, but also can be used for food therapy, are particularly suitable for administration of treatment and food therapy of patients suffering from hepatitis, fatty liver, acute and chronic inflammation, tumor, chemotherapy, diabetes mellitus and cardio-cerebrovascular disease and have no toxic or side effects.

The invention relates to a long-circulating liposome capable of avoiding an accelerated blood clearance (ABC) phenomenon, a medicine preparation containing the long-circulating liposome, and a preparation method and an application of the long-circulating liposome. The long-circulating liposome provided by the invention comprises phospholipid, auxiliary lipid and poly carboxyl betaine lipid, wherein the long-circulating liposome and the preparation thereof can be applied to medicines for treating related diseases. According to the long-circulating liposome for avoiding the ABC phenomenon provided by the invention, the defect that a common liposome is easily recognized by a reticular endothelium system is overcome; a long-circulating effect of blood is reached; meanwhile, the ABC phenomenon caused by multiple intravenous injections of the PEG-modified long-circulating liposome is avoided; the medicine effect of a therapeutic medicine is effectively improved; and the long-circulating liposome has a high application prospect in the field of medicines.

The invention relates to the medical field of immunoassay, more specially, the invention provides a chemiluminescent immunoassay detection kit for phosphatidylinositol proteoglycan-3(GPC-3) and a preparation method thereof, and realizes the simultaneous serological detection of GPC-3 N terminal and C-terminal protein with the chemiluminescent immunoassay method. The kit has the advantages of simple sampling, convenient detection and accurate and specific technical method. The invention adopts a biotin-strapavidin system to coat antibodies and improve the efficiency of antibody coating and the linear range of detection as well as sensitivity, and can be conveniently used for the tracing observation of early diagnosis or treatment effect for primary carcinoma of liver.

Disclosed is a sustained-release lipid pre-concentrate, comprising: a) at least one liquid crystal former; b) at least one neutral phospholipid; c) at least one liquid crystal hardener; and d) at least one anionic anchoring agent, wherein the sustained-release pre-concentrate exists as a lipid liquid phase in the absence of aqueous fluid and forms into a liquid crystal upon exposure to aqueous fluid. The sustained-release lipid pre-concentrate is configured to enhance the sustained release of cationic pharmacologically active substance through ionic interaction between the anionic anchoring agent and the cationic pharmacologically active substance.

The disclosed method of treating a malignant solid tumor in a subject includes the steps of administering to the subject an immunomodulatory dose of a radioactive phospholipid ether metal chelate, a radiohalogenated phospholipid ether, or other targeted radiotherapy (TRT) agent that is differentially retained within malignant solid tumor tissue, and either (a) performing in situ tumor vaccination in the subject by introducing into at least one of the malignant solid tumors one or more agents capable of stimulating specific immune cells within the tumor microenvironment, or (b) performing immunotherapy in the subject by systemically administering to the subject an immunostimulatory agent, such as an immune checkpoint inhibitor. In a non-limiting example, the radioactive phospholipid ether metal chelate or radiohalogenated phospholipid ether has the formula:

wherein R₁ comprises a chelating agent that is chelated to a metal atom, wherein the metal atom is an alpha, beta or Auger emitting metal isotope with a half-life of greater than 6 hours and less than 30 days, or wherein R₁ comprises a radioactive halogen isotope. In one such embodiment, a is 1, n is 18, m is 0, b is 1, and R₂ is —N⁺(CH₃)₃.

The invention provides a method for preparing polypeptide of Cordyceps militaris by enzymolysis and product development. Cultivated Cordyceps militaris is dried at a temperature of between 37 and 72 DEG C and is crushed into powder, a biocatalyst (enzyme) of which weight is 0.007 to 0.05 percent of the weight of the Cordyceps militaris is added, and a zymoexciter is added at the same time. The hydrolysis is performed for 3 to 6h under water bath condition that the temperature is between 25 and 55 DEG C and the pH value is between 1.0 and 10.0, then the centrifugation and ultrafiltration are performed to obtain a clear yellowy Cordyceps militaris hydrolysate, and the hydrolysis rate is between 70 and 80 percent. The Cordyceps militaris hydrolysate contains a large amount of small molecular polypeptide, growth factors, esters (phospholipid, steroid compounds, fatty acid, and so on), more than 20 amino acids, trace elements and various effective medicinal components such as cordycepin, cordycepic acid, and so on. An obtained product can be applied to a plurality of aspects such as pharmacy, health care products and food, cosmetics, and so on, has convenient application, time saving and no pollution, and can develop a plurality of new products.

The invention discloses a nanoparticle freeze-drying powder preparation containing recombinant human serum albumin. The preparation is prepared from the following components in mass percent: 0.05-5% of taxol, 0.1-50% of phospholipid, 1-60% of recombinant human serum albumin, 1-60% of freeze-drying supporting agent and 0.05-10% of PH regulating agent. In the invention, the average particle size of the obtained nanoparticles is less than 0.4mu m, and the obtained powder preparation is reproduced with water for injection, glucose and normal saline to form an injectable water solution the PH of which is 5.0-7.0, thereby greatly improving the industrialized value of the preparation.

The invention discloses a nimodipine micelle injection and a preparation method thereof. The nimodipine micelle injection is prepared by using active ingredients, i.e. nimodipine and phospholipid/bile salt. According to the nimodipine micelle injection disclosed by the invention, the solubility of the nimodipine is greatly increased, and no crystal precipitation exists when the nimodipine micelle injection is diluted; the biocompatibility of the phospholipid/bile salt is good, and organic solvents with great toxic side effects, such as ethyl alcohol, propylene glycol and the like, are not needed to for solubilizing so that the toxicity of the nimodipine micelle injection is lowered, the vascular stimulation is little, and the adverse reaction of the nimodipine micelle injection is reduced; and the nimodipine micelle injection can be directly used for intravenous injection and can also be used for instilling after the nimodipine micelle injection is diluted to various degrees, and thus, the clinical administration is greatly facilitated.

The invention belongs to the field of peanut oil extraction, and discloses a protogenic virgin peanut oil and a production process thereof. The production process comprises the following steps: (1) separating and screening; (2) peeling off the red peanut coat and stone; (3) performing magnetic separation and color separation; (4) performing chemical treatment; (5) sterilizing by using ozone; (6) baking; (7) squeezing the oil; (8) removing phospholipid. The invention further discloses the peanut oil prepared by using the production process. By adoption of the production process disclosed by the invention, the unique fragrance of peanut is retained, and harmful substances such as aspergillus flavus are thoroughly removed.

The invention discloses a method for physically refining soybean crude oil and synchronously preparing soybean concentrated phospholipids employing enzymatic degumming. The method comprises the following steps: (1) taking soybean crude oil, and adding a citric acid to homogenize; (2) adding phospholipase and/or degummase to the homogenized soybean crude oil to homogenize; (3) stewing the crude oil homogenized in the step (2) for 1.5-3 hours, and then centrifugally separating, so as to obtain degummed oil and residues; (4) carrying out decolorizing, deodorizing and deacidifying on the degummed oil which is centrifugally separated in the step (3), so as to obtain product oil; (5) adding an organic solvent to remove neutral oil in the residues which are centrifugally separated in the step (3). By adopting enzymatic degumming, not only is a water resource saved, but also the produced product oil and residues are low in moisture, the quality of the phospholipids is easily controlled, and the product is stable in quality. Thus, the economic benefits are greatly improved.

The invention belongs to the field of medicament preparations, and discloses an octreotide acetate lipidosome precursor and a preparation method thereof. The precursor lipidosome contains octreotide acetate, negatively-charged phospholipid and a cryoprotectant, and can contain an appropriate quantity of other lipids including phosphatidylchline and cholesterol; components such as an antioxidant, a pH regulating agent and the like can be added as required; the molar ratio of the octreotide acetate to the negatively-charged phospholipid is smaller than 1:1; and the mass ratio of the negatively-charged phospholipid to the cryoprotectant is 1:1-1:10. In the invention, a tert-butyl alcohol-water cosolvent freeze-drying method is adopted. The entrapment rate of an octreotide acetate lipidosome/micelle obtained by hydrating a freeze-dried product can be over 50 percent, an octreotide acetate lipidosome/micelle obtained by hydrating the freeze-dried product has high stability, and the problem of difficulty in entrapping a protein polypeptide medicament during preparation of a lipidosome/micelle preparation is solved. The preparation method is simple and practicable, and is suitable for industrial mass production.

The invention belongs to the technical field of cosmetics, and particularly relates to whitening cream and a preparation method thereof. The whitening cream comprises the following preparation raw materials of nicotinamide, resveratrol, 3-o-ethyl ascorbic acid, a peony extract, diglucosyl gallic acid, a caviar extract, phosphatidylcholine, ceramide 3, p-hydroxyacetophenone, tocopheryl acetate, sodium hyaluronate, 7-10% of a humectant, an emollient, an emulsifying agent, a thickening agent, a neutralizer, essence and water. The whitening cream disclosed by the invention can take effect in multiple ways of melanin generation inducement, melanin generation process, melanin transfer, melanin digestion and discharge process and the like, and the purpose of quickly whitening skin and dispellingfreckles can be achieved.